Literature DB >> 23062577

Bulbar muscle weakness and fatty lingual infiltration in glycogen storage disorder type IIIa.

Jeffrey J Horvath1, Stephanie L Austin, Harrison N Jones, Elizabeth J Drake, Laura E Case, Brian J Soher, Mustafa R Bashir, Priya S Kishnani.   

Abstract

Glycogen storage disorder type III (GSD III) is a rare autosomal recessive disorder resulting from a deficiency of glycogen debranching enzyme, critical in cytosolic glycogen degradation. GSD IIIa, the most common form of GSD III, primarily affects the liver, cardiac muscle, and skeletal muscle. Although skeletal muscle weakness occurs commonly in GSD IIIa, bulbar muscle involvement has not been previously reported. Here we present three GSD IIIa patients with clinical evidence of bulbar weakness based on instrumental assessment of lingual strength. Dysarthria and/or dysphagia, generally mild in severity, were evident in all three individuals. One patient also underwent correlative magnetic resonance imaging (MRI) which was remarkable for fatty infiltration at the base of the intrinsic tongue musculature, as well as abnormal expansion of the fibro-fatty lingual septum. Additionally, we provide supportive evidence of diffuse glycogen infiltration of the tongue at necropsy in a naturally occurring canine model of GSD IIIa. While further investigation in a larger group of patients with GSD III is needed to determine the incidence of bulbar muscle involvement in this condition and whether it occurs in GSD IIIb, clinical surveillance of lingual strength is recommended.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23062577     DOI: 10.1016/j.ymgme.2012.09.025

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  2 in total

1.  Natural Progression of Canine Glycogen Storage Disease Type IIIa.

Authors:  Elizabeth D Brooks; Haiqing Yi; Stephanie L Austin; Beth L Thurberg; Sarah P Young; John C Fyfe; Priya S Kishnani; Baodong Sun
Journal:  Comp Med       Date:  2016-02       Impact factor: 0.982

Review 2.  Update Review about Metabolic Myopathies.

Authors:  Josef Finsterer
Journal:  Life (Basel)       Date:  2020-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.